Table 1.
Clinicopathologic characteristics of the study subjects
| Characteristics | Total subjects (N=104) | EGFR-TKI plus WBRT (n=56) | EGFR-TKI (n=48) | P-value | ||
|---|---|---|---|---|---|---|
|
| ||||||
| No. of patients | % | No. of patients | % | |||
|
| ||||||
| Gender | ||||||
| Male | 45 | 25 | 55.6 | 20 | 44.4 | 0.843 |
| Female | 59 | 31 | 52.5 | 28 | 47.5 | |
| Age (years) | ||||||
| >60 | 37 | 19 | 51.2 | 18 | 48.6 | 0.837 |
| ≤60 | 67 | 37 | 30 | |||
| ECOG-PS score | ||||||
| 0–1 | 92 | 48 | 52.2 | 44 | 47.8 | 0.377 |
| ≥2 | 12 | 8 | 66.7 | 4 | 33.3 | |
| Symptomatic brain metastasis | ||||||
| Yes | 48 | 29 | 60.4 | 19 | 39.6 | 0.241 |
| No | 56 | 27 | 48.2 | 29 | 51.8 | |
| Smoking status | ||||||
| Never | 77 | 41 | 53.2 | 36 | 46.8 | 0.836 |
| Former | 27 | 15 | 55.6 | 12 | 44.4 | |
| EGFR mutations | ||||||
| 19 del | 39 | 18 | 46.2 | 21 | 53.8 | 0.173 |
| L858R | 39 | 20 | 51.3 | 19 | 48.7 | |
| Others | 26 | 18 | 69.2 | 8 | 30.8 | |
| Extracranial metastasis initially | ||||||
| Yes | 83 | 45 | 54.2 | 38 | 45.8 | 0.880 |
| No | 21 | 11 | 52.3 | 10 | 47.6 | |
| Number of brain metastases, n | ||||||
| >3 | 70 | 30 | 42.9 | 40 | 57.1 | 0.403 |
| ≤3 | 34 | 16 | 47.1 | 18 | 52.9 | |
| Histology | ||||||
| Adenocarcinoma | 101 | 56 | 55.4 | 45 | 44.6 | 0.095 |
| Others | 3 | 0 | 0 | 3 | 100 | |
Abbreviations: ECOG-PS, Eastern Cooperative Oncology Group Performance Status; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiotherapy.